Trial · NCT00755079
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
NCT00755079, Phase 2, Phase 3, Completed, US Department of Veterans Affairs; results first posted 2014-07-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury. Trials, record NCT00755079. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00755079
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
- NCT number
- NCT00755079
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 40 participants, actual
- Lead sponsor
- US Department of Veterans Affairs
- Conditions
- Spinal Cord Injury
- Interventions
- extended release beta-2 adrenergic agonist, placebo
- First posted
- 2008-09-18
- Last updated
- 2015-03-17
- Results first posted
- 2014-07-16
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Inspiratory Respiratory Muscle Strength | Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment. | Respiratory muscle strength as measured by maximal inspiratory and pressures at the mouth. |
| Secondary | Expiratory Respiratory Muscle Strength | Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment. | Respiratory Muscle Strength defines as Maximal expiratory muscle strength at the mouth. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Inspiratory Respiratory Muscle Strength | Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment. | cmH2O | MEAN | |
| SECONDARY | Expiratory Respiratory Muscle Strength | Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment. | cmH2O | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Inspiratory Respiratory Muscle Strength | Placebo Control | Maximal Inspiratory Pressure Baseline | 82.35 | Standard Deviation 18.07 | cmH2O |
| Inspiratory Respiratory Muscle Strength | Active Drug | Maximal Inspiratory Pressure Baseline | 79.19 | Standard Deviation 29.72 | cmH2O |
| Inspiratory Respiratory Muscle Strength | Placebo Control | Maximal Inspiratory Pressure 12wk Post | 85.31 | Standard Deviation 24.51 | cmH2O |
| Inspiratory Respiratory Muscle Strength | Active Drug | Maximal Inspiratory Pressure 12wk Post | 91.69 | Standard Deviation 32.04 | cmH2O |
| Expiratory Respiratory Muscle Strength | Placebo Control | Maximal Expiratory Pressure Baseline | 84.65 | Standard Deviation 36.82 | cmH2O |
| Expiratory Respiratory Muscle Strength | Active Drug | Maximal Expiratory Pressure Baseline | 70.38 | Standard Deviation 35.95 | cmH2O |
| Expiratory Respiratory Muscle Strength | Placebo Control | Maximal Expiratory Pressure 12 week | 88.31 | Standard Deviation 30.12 | cmH2O |
| Expiratory Respiratory Muscle Strength | Active Drug | Maximal Expiratory Pressure 12 week | 77.44 | Standard Deviation 37.89 | cmH2O |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo Control | 18 | |
| Overall Study | STARTED | Active Drug | 22 | |
| Overall Study | COMPLETED | Placebo Control | 17 | |
| Overall Study | COMPLETED | Active Drug | 16 | |
| Overall Study | NOT COMPLETED | Placebo Control | 1 | |
| Overall Study | NOT COMPLETED | Active Drug | 6 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Muscle Cramping | Musculoskeletal and connective tissue disorders | Placebo | 0 | 18 | 0 |
| serious | Muscle Cramping | Musculoskeletal and connective tissue disorders | Active Drug | 1 | 22 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Active Drug | ||
| Total, other adverse events | Placebo | 0 | 18 |
| Total, other adverse events | Active Drug | 0 | 22 |
| Total, serious adverse events | Placebo | 0 | 18 |
| Total, serious adverse events | Active Drug | 1 | 22 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Active Drug vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00755079
GET https://conductscience.org/api/trials/v1/NCT00755079/registered